Suplatast (Tosilate)

Suplatast Tosilate (IPD 1151T) is an orally active Th2 cytokine inhibitor which can inhibit both IL-4 and IL-5 production from Th2 cells and suppress IgE synthesis. Suplatast Tosilate is an anti-allergic agent. Suplatast Tosilate has antiasthmatic, anti-inflammatory and antifibrotic activity[1][2][3][4].

Product Specifications

CAS Number

[94055-76-2]

Product Name Alternative

IPD 1151T

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Suplatast-Tosilate.html

Purity

99.67

Solubility

DMSO : ≥ 33 mg/mL|H2O : ≥ 100 mg/mL

Smiles

C[S+](C)CCC(NC1=CC=C(C=C1)OCC(COCC)O)=O.CC2=CC=C(C=C2)S(=O)([O-])=O

Molecular Formula

C23H33NO7S2

Molecular Weight

499.64

Precautions

H302, H315, H319, H335

References & Citations

[1]Furonaka M, Hattori N, Tanimoto T, Senoo T, Ishikawa N, Fujitaka K, Haruta Y, Yokoyama A, Kohno N. Suplatast tosilate prevents bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther. 2009 Jan;328 (1) :55-61.|[2]Yanagihara Y, et, al. Suppression of IgE production by IPD-1151T (suplatast tosilate), a new dimethylsulfonium agent: (2) . Regulation of human IgE response. Jpn J Pharmacol. 1993 Jan;61 (1) :31-9.|[3]Zhao GD, et, al. Effect of suplatast tosilate (IPD-1151T) on a mouse model of asthma: inhibition of eosinophilic inflammation and bronchial hyperresponsiveness. Int Arch Allergy Immunol. 2000 Feb;121 (2) :116-22.|[4]Kurokawa M, et, al. Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo. Mediators Inflamm. 2001 Dec;10 (6) :333-7.